J Gen Virol Tips for Better Browsing
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Gen Virol 69 (1988), 1941-1948; DOI 10.1099/0022-1317-69-8-1941
© 1988 Society for General Microbiology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huovilainen, A.
Right arrow Articles by Hovi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huovilainen, A.
Right arrow Articles by Hovi, T.
Agricola
Right arrow Articles by Huovilainen, A.
Right arrow Articles by Hovi, T.

Antigenic Variation among 173 Strains of Type 3 Poliovirus Isolated in Finland during the 1984 to 1985 Outbreak

Anita Huovilainen1, Leena Kinnunen1, Morag Ferguson2 and Tapani Hovi1

1 Enterovirus Laboratory, Department of Virology, National Public Health Institute, Mannerheimintie 166, SF-00280 Helsinki, Finland
and2 Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire EN6 3QG, U.K.

Antigenic properties of 128 clinical type 3 poliovirus isolates of the 1984 to 1985 Finland outbreak from 95 persons and 45 strains from sewage water specimens were evaluated using five neutralizing monoclonal antibodies (MAbs) directed against an antigenic site (designated site 1) on VP1 at amino acids 89 to 100. All five MAbs neutralized the type 3 poliovirus strains used in the vaccines, P3/Saukett and P3/Sabin, but none of them neutralized the prototype strain of the outbreak (P3/Finland/23127/84). Forty-six percent of the clinical isolates resembled the prototype strain (class A) while the rest of the isolates were neutralized by one or more of the MAbs (classes B to D). Although an antigenic drift from A to one of the other classes was observed in sequential specimens from several individuals, no clear-cut overall change in the class distribution was found within the 3 months time span of the outbreak. Homogeneous virus populations were isolated from the sewage specimens using a microtitre endpoint dilution method. The last positive sewage specimens which were obtained in January to February 1985 still had a majority of the class A strain. Some of the clinical isolates were also tested using MAbs directed against distinct antigenic sites. These studies showed that strains that gave the same pattern of reactivity with site 1 MAbs could be differentiated using antibodies directed against other sites. Fifteen strains belonging to different antigenic subclasses were subjected to partial RNA sequencing of the genome region coding for antigenic site 1. The antigenic variation was usually, but not always associated with corresponding amino acid substitutions in antigenic site 1. These results indicate that the antigenic sites of type 3 poliovirus vary extensively within a given outbreak and even during replication in a given host. This variation may have both pathogenetic and epidemiological significance.

Keywords: poliovirus, antigenic variation, subclasses of poliovirus

Received 17 February 1988; accepted 16 May 1988.


This article has been cited by other articles:


Home page
J. Gen. Virol.Home page
T. Hovi, N. Lindholm, C. Savolainen, M. Stenvik, and C. Burns
Evolution of wild-type 1 poliovirus in two healthy siblings excreting the virus over a period of 6 months
J. Gen. Virol., February 1, 2004; 85(2): 369 - 377.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
S. Blomqvist, A.-L. Bruu, M. Stenvik, and T. Hovi
Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1
J. Gen. Virol., March 1, 2003; 84(3): 573 - 580.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
M. Mulders, J. Reimerink, M Stenvik, I Alaeddinoglu, H. van der Avoort, T Hovi, and M. Koopmans
A Sabin vaccine-derived field isolate of poliovirus type 1 displaying aberrant phenotypic and genetic features, including a deletion in antigenic site 1
J. Gen. Virol., April 1, 1999; 80(4): 907 - 916.
[Abstract]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 1988 by the Society for General Microbiology.